880348-28-7

Upstream product

• 880386-25-4 3-bromo-4-fluoro-L-phenylalanine 
• 108-24-7 acetic anhydride 
• 1361513-61-2 (Z)-methyl 2-acetamido-3-(3-bromo-4-fluorophenyl)acrylate 
• 1361513-62-3 (Z)-2-acetamido-3-(3-bromo-4-fluorophenyl)acrylic acid 
• 77771-02-9 3-bromo-4-fluorobenzaldehyde 
• 880348-26-5 2-acetylamino-3-(3-bromo-4-fluorophenyl)acrylic acid 

Downstream Products

• 880386-25-4 3-bromo-4-fluoro-L-phenylalanine 
• 1297599-47-3 2-(2-amino-4,5-dichlorobenzoylamino)-3-(3-bromo-4-fluorophenyl)propionic acid 
• 1297599-48-4 2-{3-[2-(3-bromo-4-fluorophenyl)-1-carboxyethyl]ureido}-4,5-dichlorobenzoic acid 
• 880386-23-2 C₁₀H₁₁BrFNO₂ 

Relevant academic research and scientific papers

Enantioselective access to chiral drugs by using asymmetric hydrogenation catalyzed by Rh(P-OP) complexes

P-OP art: Rhodium complexes of P-OP ligands serve as highly efficient and enantioselective catalysts in asymmetric hydrogenation leading to various valuable pharmaceutical building blocks and several direct precursors of chiral drugs such as LY2497282, la

Protecting-group-free synthesis of a dual CCK1/CCK2 receptor antagonist

In our pursuit of an efficient, protecting-group-free synthesis of the dual CCK1/CCK2 receptor antagonist 1, we have developed chemoselective conditions for sulfonamide formation reaction in pure water and a PhNMe2 mediated carboxamide formatio

SULFONAMIDE COMPOUNDS

Certain sulfonamide compounds are dual CCK1/CCK2 inhibitors useful in the treatment of CCK1/CCK2 mediated diseases.